Han et al. tested the effectiveness of tyrosine kinase inhibitor (TKI) therapy by treating a patient with recurrent metastatic MEC who progressed on multiple chemotherapy regimens with the EGFR-specific TKI gefitinib. This evidence concerns the gene EGFR and mucoepidermoid carcinoma.